The promise and pitfalls of composite endpoints in sepsis andCOVID-19 clinical trials

被引：2

作者：

Brown, P. M. ^{[1
,2
]}

Rogne, Tormod ^{[1
,3
]}

Solligard, Erik ^{[1
,3
]}

机构：

[1] Trondheim Reg & Univ Hosp, St Olavs Hosp, Gemini Ctr Sepsis Res, Clin Anesthesia & Intens Care, Trondheim, Norway

[2] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway

[3] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Trondheim, Norway

来源：

PHARMACEUTICAL STATISTICS | 2021年 / 20卷 / 02期

关键词：

HEART-FAILURE; DESIGN; MORTALITY;

D O I：

10.1002/pst.2070

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.

引用

页码：413 / 417

页数：5

共 39 条

[1]

[Anonymous], CPMPEWP298603

[2] Examining the Influence of Component Outcomes on the Composite at the Design Stage [J].